Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8936 results

  1. Sigvotatug vedotin for Non-small-cell lung cancer [ID6718]

    Awaiting development Reference number: GID-TA11942 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Efzimfotase alfa for treating hypophosphatasia [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331]

    Awaiting development Reference number: GID-TA11936 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Selinexor + pomalidomide + dexamethasone for Multiple myeloma [TSID12333]

    Awaiting development Reference number: GID-TA11938 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [TSID12341]

    Awaiting development Reference number: GID-TA11941 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Bictegravir-Lenacapavir for HIV-1 infection [TSID12343]

    Awaiting development Reference number: GID-TA11943 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Suspected sepsis: recognition, diagnosis and early management - procalcitonin testing

    In development Reference number: GID-NG10467 Expected publication date:  15 July 2026

    NICE guideline
    In development

  8. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]

    Awaiting development Reference number: GID-TA11215 Expected publication date:  07 May 2026

    Technology appraisal guidance
    Awaiting development

  10. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]

    Awaiting development Reference number: GID-TA11920 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma [ID6701]

    Awaiting development Reference number: GID-TA11935 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. 12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]

    In development Reference number: GID-TA11635 Expected publication date:  26 August 2026

    Technology appraisal guidance
    In development

  14. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  15. Aggressive behaviour in people receiving NHS or social care: prevention and management

    In development Reference number: GID-NG10432 Expected publication date:  28 January 2027

    NICE guideline
    In development